Trial Profile
An Open-Label Long-Term Safety Study of Serlopitant for the Treatment of Pruritus
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 07 Apr 2022
Price :
$35
*
At a glance
- Drugs Serlopitant (Primary)
- Indications Pruritus
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors VYNE Therapeutics
- 06 Apr 2022 This trial has been completed in Poland (Date of the global end of the trial : 08-Apr-2020), according to European Clinical Trials Database record.
- 14 Aug 2020 Status changed from active, no longer recruiting to discontinued. Reason the study was stopped: No longer pursuing development of serlopitant.
- 06 May 2020 This trial has been discontinued in Austria as per European Clinical Trials Database record